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Background: Although there are numerous case reports and small case series describing the experiences of leech therapy in various cir-
cumstances, there are relatively few large studies evaluating the effectiveness of leeching to relieve venous congestion. The therapeutic
value of leeching is illustrated by these reports but the current literature lacks a cohesive summary of previous experiences. Methods: An
electronic search of PubMed, the Cochrane library and the Centre for Reviews and Dissemination between 1966 and 2009 was used to
retrieve human studies published in the English language evaluating outcomes following leech therapy. The ‘success’ and ‘failure’ of leech
therapy were the primary outcome measures and secondary outcomes included complications, number of leeches used, pharmacological
adjuncts and blood transfusion requirements. Results: In total, out of 461 articles, 394 articles met the exclusion criteria. The 67 included
papers reported on 277 cases of leech use with an age range of 2–81 years and a male to female ratio of almost 2:1. The overall reported
‘success’ rate following leech therapy was 77.98% (216/277). In terms of secondary outcome measures, 49.75% of cases (N 5 101)
required blood transfusions, 79.05% received antibiotics (N 5 166) and 54.29% received concomitant anticoagulant therapy. The overall
complication rate was 21.8%. Conclusion: In the absence of robust randomized controlled trials on which the evidence may be based, this
synthesis of current best evidence guides clinicians during the process of consenting patients and using leeches in their practice. VC 2012
Wiley Periodicals, Inc. Microsurgery 32:240–250, 2012.
Bloodletting and the therapeutic use of medicinal leeches
dates back to ancient Egypt.1 Decades of reports of leech
therapy in plastic and reconstructive surgery2 and more
recently the application of leeching for medical prob-
lems3–6 has given Hirudo therapy a niche in contempo-
rary medical practice. Plastic,7–10 maxillofacial,11 and
other reconstructive surgeons12,13 use leeches to aid sal-
vage of compromised pedicled ﬂaps,2,14 microvascular
free-tissue transfers15–17 and venously congested extrem-
ities including digits,9,18–25 nipples,26,27 ears,28–32
lips,33,34 nasal tips,12,35 and the penis.36 After many years
of use, Hirudo medicinalis received ofﬁcial FDA ap-
proval as a medical device in 2004.37
Leeches are useful to the reconstructive surgeon, as
venous anastomoses can either become compromised or
are not even attempted. When anastomoses are per-
formed, venous thrombosis is a more common complica-
tion than arterial thrombosis38 and it has been demon-
strated in experimental ﬂaps that acute venous obstruction
is more damaging than acute and complete pedicle
obstruction, where both arterial and venous supplies are
involved.39–41 There are a small number of experimental
studies quantifying leech efﬁcacy. A randomized control
trial of leech treated venous compromised rodent epigas-
tric skin ﬂaps demonstrated a signiﬁcant increase in ﬂap
survival rate,42 and in a leech treated porcine model of
venous compromised ﬂaps, improved blood ﬂow was
objectively demonstrated using laser Doppler perfusion
monitoring. In a case of human ear replantation, quantita-
tive measurements of blood ﬂow using injected ﬂuores-
cein demonstrated an improvement of venous congestion
after leech application.43 The increased blood ﬂow found
throughout the leech treated ﬂap is thought to be due to a
combination of bleeding relieving obstruction and thus
capillary pressure, and also by effects on the microcircu-
lation caused by injection of the leech’s vasoactive secre-
tions.44
Although there are numerous case reports and small
case series describing the experiences of leech therapy in
various circumstances, there are relatively few large stud-
ies evaluating the effectiveness of leeching to relieve ve-
nous congestion.2,23,45,46 Although the therapeutic value
of leeching is illustrated by these reports, the current lit-
erature lacks a cohesive summary of previous experien-
ces. The aim of this paper is to present current best evi-
dence regarding the use of leeches by reviewing 277
cases retrieved from the literature. In the absence of ro-
bust randomized controlled trials on which the evidence
may be based, such a synthesis of current best evidence
may serve to elucidate the efﬁcacy of leech therapy, and
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guide clinicians during the process of consenting patients
and using leeches on their own patients.
METHODS
The search string (‘‘Leeches’’[Mesh] OR ‘‘Lee-
ching"[Mesh]) AND (‘‘Therapeutics"[Mesh] OR ‘‘therapy
‘‘[Subheading] OR ‘‘Treatment Outcome"[Mesh]) in Bool-
ean format was used across the PubMed Database of the
US National Library of Medicine, the Cochrane library and
the Centre for Reviews and Dissemination. Bibliographic
secondary linkage was used to retrieve additional papers.
The time frame covered was 1966 to May 2009.
Inclusion Criteria
1. Human studies published in the English language and
evaluating the outcomes following leech therapy for
venous congestion of ﬂaps and replanted appendages.
Exclusion Criteria
1. Articles including only descriptive data, historical
articles, correspondence, editorials, and reviews
2. Studies with inadequate information or information
that is not clearly portrayed or tallied, or studies that
data cannot be used or extracted, speciﬁcally for the
primary outcome.
Outcome Measures
The ‘‘success’’ and ‘‘failure’’ of leech therapy were
the primary outcome measures. ‘‘Success’’ was deﬁned as
survival of the tissue/ﬂap (even if a small amount of the
ﬂap needed debridement); whereas ‘‘failure’’ was consid-
ered to occur when excision of the whole ﬂap or append-
age was required or further procedure(s) were needed af-
ter leeching with or without secondary reconstruction.
Secondary outcomes included complications directly
caused by the leech therapy, total number of leeches
used, the use of pharmacological adjunctives and the
requirements for blood transfusion. The type of study
design was also evaluated.
Data Extraction and Analysis
A data extraction proforma was used for each article
included in the review. All included studies and extracted
data were further appraised by another author to ensure
the accuracy of the collected data. Outcomes were only
included in the analysis if they were speciﬁcally stated,
and no assumptions were made on unreported (missing)
data; speciﬁcally, when a particular rate was not dis-
closed it was not assumed to be zero.
Figure 1. Citation attrition diagram documenting search process for the systematic review evaluating leech therapy for venous congestion
post reconstructive or replantation surgery.
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Table 1. Detailed Analysis of the 67 Papers That Met Inclusion Criteria For Describing the Use of Leeches in Reconstructive Surgery
First author
Year
published Type of tissue
Sex (M, male;
F, female;
Age (years) Total Survived Failed
Number of
leeches used
Therapy time
(mean;
range) (days)
Derganc2 1960 Flaps NM 20 20 0 3-6 BD – TDS NM
Baudet54 1976 Free ﬂap M; 38 1 1 0 NM 2
Henderson55 1983 Scalp replantation M; 28 1 1 0 4–8 every
12 hours
5
Holtje33 1984 Lip replantation M; 44 1 1 0 100 10
Batchelor6 1984 Various M:F 5 6:1; 17–81 7 7 0 1 BD – 2 QDS 2.8; 2–4
Dickson56 1984 Pedicled Flap F; 27 1 1 0 NM 4
Rao57 1985 Various 6M, 1F; 8–79 7 6 1 1 leech every 2
days – 1 QDS
5.3; 4–7
Lim58 1986 Free ﬂap M; 7 1 1 0 1 QDS 7
Mutimer59 1987 Ear replantation M; 3 1 1 0 Continuous 7
Makin60 1987 Penile
reconstruction
M; 44 1 1 0 2 OD 2
Mercer50 1987 Various NM 6 6 0 NM NM
Lucht61 1988 Free Flap M; 47 1 0 1 NM 5
Baker62 1989 Digital replantations M; 65 1 0 1 2–5 at all times 14
Brody17 1989 Digital replantations M:F 5 5:2; 4–57 7 6 1 1 BD 4.86; 3–6
Anthony43 1989 Ear replantation M; 25 1 0 1 25 7
Bates63 1989 Various M:F 5 1:1; 25 & 44 2 1 1 20, 3 2
Snower64 1989 Free Flap F; 62 1 0 1 NM NM
Sadove 65 1990 Ear replantation M; 21 1 1 0 1 QDS 5
Wade 66 1990 Various M:F 5 1:1; 24–46 4 4 0 NM 1–3
Evans67 1990 Hand Congestion M; 40 1 0 1 4 applied, then
continuously
4
Regan68 1991 Degloving Injury M; 16 & 27 2 2 0 20 in 1st 7 days,
3–5 leeches/day
for 2 weeks
1–2 weeks
Casady69 1991 Digital replantations M; 46 1 1 0 6 3
Crawford70 1991 Lip replantation F; 22 1 1 0 4 4
Lineaweaver7 1991 Various M:F 5 3:1; 11–63 4 4 0 4,18, 2 TDS, NM 3, 5, 6, NM
Rouholamin71 1991 Various M:F 5 7:1; 17–68 8 4 4 3 TDS 4–5
Foucher46 1992 Digital replantations NM 33 20 13 NM 5
Husami72 1992 Lip replantation M; 23 1 1 0 NM 9
Gross25 1992 Nipple Congestion F; 20 2–60 4 2 2 10, 3, 2, 40 10, 3, 1, 7
Lineaweaver8 1992 Various NM 7 1 6 NM NM
Wells73 1993 Digital replantations M; 19 1 1 0 1 every 4 hours 7
Rapaport74 1993 Ear replantation M; 38 1 1 0 1 QDS 7
Gilhooly75 1993 Free ﬂap M; 67 1 1 0 3 OD 4
Hirase76 1993 Lip replantation M; 34 1 1 0 19 7
Soucacos77 1994 Free ﬂap M:F 5 4:1; 12–73 20 17 3 2–50 5; 1–10
Soucacos22 1994 Various M:F 5 22:7, 12–73 29 24 5 2–50; 2.7 leeches
per day
Mean 5
Haycox78 1995 Free ﬂap M; 58 1 1 0 NM 22
Troum79 1995 Various NM 13 9 4 NM NM
Funk29 1996 Ear replantation M; 28 1 1 0 1 TDS 5
Pantuck12 1996 Penile replantation M; 37 1 1 0 1 OD–BD 5
de Chalain44 1996 Various M:F 5 1:2; 10–80 18 13 5 NM 3.3; 1hour–9 days
Varghese80 1996 Pedicled Flap M; 67 1 0 1 2 BD 4
Walton34 1998 Lip replantation M:F 5 4:7; 2–49 11 11 0 NM 1 – 8
Mortenson35 1998 Pedicled ﬂaps M; 18 1 1 0 2 QDS 2
Utley16 1998 Pedicled ﬂaps M; 50–76 4 4 0 2, 6, 12 and
1 every
2–4 hours
2 hours,
1–4 days
Pereira81 1998 Digital replantation F; 21 1 0 1 1 QDS 3
Cho27 1999 Ear replantation M; 37 1 1 0 13 hrly and
gradually
decreased
7
Guneren26 2000 Nipple congestion F; 24 1 1 0 1 TDS 3
Irish82 2000 Pedicled ﬂaps M; 55, 54 2 2 0 2, 4 QDS 4, 6
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RESULTS
The article selection process for evaluating leech ther-
apy for venous congestion post reconstructive or replanta-
tion surgery is displayed in Figure 1. In total, out of 461
articles, 394 articles met the exclusion criteria. Of the 67
included papers (see Table 1), one by de Chalain et al. and
the other by Foucher et al., were not included as the
authors had included the same data in subsequent papers
where they reviewed their practices and presented it within
a case series.28,45–47 The case series by Foucher et al. had a
total of 42 patients in which leech therapy was used, but
only information on 33 patients was presented in the paper.
The case report presented by Lineaweaver et al. reporting a
latissimus dorsi lower limb reconstruction was excluded as
the leeches failed to attach to the ﬂap, and surgery ulti-
mately was successful.9 The indications for leech applica-
tion are presented in Figure 2, and a topographical repre-
sentation of the uses of leech therapy in clinical practice is
illustrated in Figure 3.
Primary Outcomes
Of the 65 included papers published between 1960
and 2008, there were 27 case series, 38 case reports and
no randomized controlled trials. The relative number of
publications per year can be seen in Figure 4. One paper
presented a review of the literature prior to 1994 and a
risk beneﬁt discussion, which also included the author’s
observational study of their practice.45 There were six
articles/case reports focusing on digital replantations,19,47–51
1 hand,52 2 ring avulsions,24,53 8 on ear replanta-
tions,29,43,54–59 6 lip replantations,33,34,60–63 1 degloving
injury,64 1 scalp replantation,65 3 penile replanta-
tions,36,66,67 and 1 reconstruction,68 2 nipple congestions
post breast surgery,26,27 and 9 free ﬂap series69–77 and 25
Table 1. (Continued)
First author
Year
published Type of tissue
Sex (M, male;
F, female;
Age (years) Total Survived Failed
Number of
leeches used
Therapy time
(mean;
range) (days)
Akyurek83 2001 Ear replantation M; 35 1 0 1 1 every hour for 3
days, then 1
every 2 hours
thereafter
14
Chepeha47 2002 Free ﬂap M:F 5 3:1; 49–73 8 8 0 3 per hour 6.6; 3–10
Guven84 2002 Ring avulsion injury M; 35 1 1 0 1 leech 6 times a
day
5
Sartor51 2002 Various NM 7 2 5 5–17; mean 10.1 4.7; 3–7
Gideroglu13 2003 Pedicled ﬂaps M:F 5 4:1; 39–58 5 4 1 2–3 QDS 4.4; 3–6
Ribuffo85 2004 Free ﬂap F; 42 1 1 0 2 daily 5
Duroure86 2004 Lip replantation F; 29–61 3 2 1 NM 6
Mineo87 2004 Penile replantation M; 32 1 1 0 1 every 3–4 hours
(total of 6)
20 hours
Tuncali23 2004 Ring avulsion injuries F; 48,60 2 2 0 1 every 4–6 hours 7–10
Frodel11 2004 Various M 4 4 0 1 TDS–QDS 3–4
Ouderkirk88 2004 Flap M; 40 1 0 1 NM NM
Lazarou89 2006 Penile replantation M; 25 1 1 0 12 hourly for 6 days
then decreased
25
Ardehali 90 2006 Pedicled Flap F; 47 1 1 0 NM 5
Hullett30 2007 Replantation M; 33 1 1 0 1 BD 3
O’Toole91 2008 Ear replantation M; 60 1 1 0 Continuous 12
Ward92 2008 Pedicled ﬂaps M; 60 1 1 0 1 leech 5 times a
day
4
NM, not mentioned; OD, once daily; BD, twice daily; TDS, three times per day; QDS, four times per day.
Figure 2. Distribution of the relative salvage rates with the use of
leech therapy by literature review. [Color ﬁgure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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articles including a variety of ﬂaps or mixed case se-
ries2,7,12,14,16–18,23,35,45,78–91 (See Table 1). The included
articles yielded a total of 277 patients receiving leech ther-
apy, with an age range of 2–81 years and a male to female
ratio of almost 2:1. The overall reported ‘‘success’’ rate fol-
lowing leech therapy was 77.98% (216/277). The tissues
were deemed unsalvageable and excised in 22.02% (61 out
of 277) of the cases.
The distribution of the relative salvage rates are illus-
trated in Figure 2. Free ﬂaps (26.71%), were the most
common indication for leech therapy in this series, fol-
lowed by digital replantations (24.91%), pedicled ﬂaps
(13.36%), various ﬂaps (where the author did not differ-
entiate between free or pedicled) (7.58%), lip replanta-
tions (7.22%), ear replantations (5.05%), distal upper
limb replantations (the authors did not differentiate
between digits and the limbs) (4.69%), scalp replantations
and degloving injuries (2.17%), proximal upper limb
replantations (1.81%), ring avulsions, penile replantations,
and nipple congestions (1.08%). One penile reconstruc-
tion, a single congested hand and one nose avulsion
(0.36%) completed the series. The 100% success rate of
the small number of ring avulsions, nose avulsion, penile
replantations and reconstruction, and nipple congestion
were encouraging, although the small numbers involved
preclude any meaningful inferences. The lip replantation
group fared well, with an overall success rate of 95%.
The digital replantation group reported a salvage rate of
62.3% which is only slightly lower than the reported suc-
Figure 3. Topographical representation of the reported use of leeches in reconstructive surgery. [Color ﬁgure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
Figure 4. The relative number of publications reporting the use of
leeches in reconstructive surgery over time.
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cesses of Foucher in his seminal series.47 Mixed ﬂaps’
failure rate was 4.76%.
Number of Leeches Used
The number of leeches was highly variable, ranging
from one leech per day to as many as one every hour.
The time interval between applications was similarly var-
ied, ranging from hourly to once a day for 22 days.
Blood Transfusion
Blood transfusion is often required for patients due to
the continuous blood loss during and for several hours
following leech therapy (see Fig. 5). Thirteen (13) articles
did not mention whether or not blood transfusion was
required. Out of the 52 articles reporting the use of blood
transfusions, 49.75% of cases (N 5 101) required blood
transfusions.
Adjunctive Pharmacotherapy
Eleven (11) articles did not mention whether or not
any type of adjunctive medication was used (See Fig. 6).
Of the remaining 54 articles, 79.05% of their patients
received antibiotics (N 5 166), 54.29% received concom-
itant anticoagulant therapy (N 5 114), and 3.33% (N 5
7) received antispasmodics. One patient (0.48%) received
sildenaﬁl.
Complications
Of the 61 articles reporting on complications, 18
articles reported complications of leech therapy (See Fig.
7). Of the 229 patients described in the 61 articles, there
was a 21.8% complication rate (n 5 50). The infective
complication rate was 14.4% (N 5 33). Rare complica-
tions (<3% each) included leech bite scars, psychosis,
prerenal azotemia and very rarely, pain (N 5 1, 0.4%).
The complications that were not related to leech therapy
were not reviewed.
Infection vs. Noninfected
Of the 33 patients that developed an infection, the
replant/ﬂap savage rate was 37.4% (N 5 12) (See Fig.
8). In the 196 patients where an infection was not
encountered, the tissue survival rate was 88.3% (N 5
173).
The reported pathogens responsible for the infections
are reported in Figure 9.
Figure 6. The reported use of adjunctive medications to aid the
use of leech therapy. [Color ﬁgure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
Figure 7. Reported complications associated with the use of
leeches. [Color ﬁgure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
Figure 5. The reported need for blood transfusion, by units of
blood, associated with the use of leeches. [Color ﬁgure can be
viewed in the online issue, which is available at wileyonlinelibrary.
com.]
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Blood Transfusion vs. No Transfusion
The salvage rate of the tissues in which patients
required blood transfusion was 82.2% (83/101) and in
those who did not require blood transfusion, the tissue
survival rate was 91.2% (93/102) (See Fig. 10).
DISCUSSION
The reporting of individual case reports and small se-
ries of patients having leech therapy, after peaking in the
early 1990s, has become less frequent as the publication
of novel information becomes less likely. This trend may
reverse as the importance of the different species of me-
dicinal leech in use, and the potential differences are fur-
ther investigated. The European medicinal leech is one of
vanishingly few animal species with direct application in
modern medicine and Hirudo medicinalis has been
approved by the United States Food and Drug Adminis-
tration as a prescription medical device. However a
recent article has highlighted that there are at least three
species of European medicinal leech, and that leeches
marketed as Hirudo medicinalis are actually Hirudo ver-
bena.92
This study of 277 cases from the literature exhibited
a wide reported range of indications along with a good
overall efﬁcacy of leech therapy. Our data, in line with
previous studies, support the use of leeches to aid salvage
of replanted extremities and free tissue transfers. It is im-
portant to note that tissues should be assessed clinically
before application of leeches, and there is experimental
evidence that they should not be used to attempt salvage
when there is mixed arterio-venous insufﬁciency. A well
designed rat study showed that the use of multiple
leeches was detrimental to ﬂap survival.93
Almost 50% of our dataset (52 articles/101 cases
reporting on the use of blood transfusions) required blood
transfusions. The need for blood transfusion during and
after leech therapy is a well-known phenomenon45,76,94
due to the continuous blood loss after leech removal. It is
advised to check the full blood counts of patients before
and after leech therapy, especially children. Our ﬁndings
show that the need for blood transfusion was not associ-
ated with a decreased salvage rate, nor were the other
rare complications including leech bite scars, psychosis,
and prerenal azotemia.
Of the 54 articles reporting on the use of pharmaco-
therapy alongside leech therapy, almost 80% of patients
received antibiotics (N 5 166), over 50% received con-
comitant anticoagulant therapy (N 5 114), and a small
number received antispasmodics.
Figure 10. Salvage-related outcomes of leech therapy for patients
who did or did not require blood transfusion. [Color ﬁgure can be
viewed in the online issue, which is available at wileyonlinelibrary.
com.]
Figure 8. Outcomes of leech therapy in the presence or absence
of infection. [Color ﬁgure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
Figure 9. Pathogens cultured from soft-tissue infections that
occurred in the presence of leech therapy. [Color ﬁgure can be
viewed in the online issue, which is available at wileyonlinelibrary.
com.]
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The overall complication rate associated with leech
therapy of 21.8% was relatively high. The infective com-
plication rate of 14.4% (N 5 33) gives more credence to
the policy of antibiotic prophylaxis such as quinolones,
which have good resistance proﬁles to Aeromonas spe-
cies. Previous reviews have reported infection rates of
between 4.1 and 20%.18,45,80,87,95,96 The review by de
Chalain et al. (1960–1994) reported an infection rate of
17.59%, though there was no clear methodology on how
the literature review was conducted and which reports
were included or excluded.45 Aeromonas hydrophila was
reported as the commonest cause of infection (87.9% of
total infections), but we now know that these were likely
to have been misidentiﬁed,97,98 and Aeromonas veronii99–
101 was the likely pathogen. Isolated reports of infections
due to Serratia marsescens,51 and Vibrio ﬂuvialis86 were
also reported. The knowledge regarding leech microbiota
is advancing due to new molecular methods to identify
the culturable and non-culturable symbionts of the leech.
In the noninfected group the salvage rate was 88.3%
which dropped to 37.4%, when the tissue became
infected. These results are broadly in line with the second
largest series from the literature reporting on the effect of
infection, de Chalain’s meta-analysis, which reported on
a total of 19 cases of Aeromonas infection (nine replants,
three free ﬂaps, and seven pedicled ﬂaps) with an overall
salvage rate of 31.8%, compared with a salvage rate of
60–80% in noninfected tissues.45 In our experience, and
that of others, surgical site infections (SSIs) due to leech
application result in additional antibiotic therapy,
extended hospital stays, rehospitalization or removal of
nonviable tissues.87 A recent clinical study has shown the
proportion of patients becoming infected after leech ther-
apy was signiﬁcantly greater in the group of patients that
did not receive a prophylactic antibiotic treatment.95
There is emerging evidence from recent studies that high
levels of resistance to ﬁrst generation cephalosporins,
penicillins (via b-lactamases), tetracyclines, and augmen-
tin are present. Fluoroquinoles seem to be consistently
active, and our experience suggests that prophylactic ﬂuo-
roquinolones seem to be mandatory given the preponder-
ance of infection.102 The recently reported case of a
MDR (multi drug resistant) Aeromonas strain is concern-
ing103 when you combine this ﬁnding with recent envi-
ronmental isolates from European natural water sources
demonstrating a plasmid mediated ﬂuoroquinolone resist-
ance in Aeromonas strains. Isolates obtained from a Swiss
lake and the Seine River containing Aeromonas with the
qnrS2 plasmid that encodes ﬂuoroquinolone resistan-
ce.104N
It is important to note the limitations of this study.
The ﬂap size is not mentioned in the papers, and the
whole idea of ‘‘success and failure’’ is easier to address
with relatively small replantations, whereas it is much
more difﬁcult in large ﬂaps. Several articles did not
include information regarding complications, the need for
blood transfusion, or whether and adjunctive medication
was used. A signiﬁcant number of papers do not com-
ment on antibiotic prophylaxis or treatment, or what type
of antimicrobials was used. The number of leeches was
highly variable, ranging from one leech per day to as
many as one every hour, indicating there is no scientiﬁc
basis as yet to guide us. The time interval between appli-
cations was similarly varied, ranging from hourly to once
a day for 22 days.
Key Practice Guidelines
 A type and screen (crossmatch) should be sent before
the onset of leeching and kept up to date.
 Leeches should not be administered to patients unwill-
ing to have a blood transfusion if there is any other al-
ternative available—and if it is necessary, there should
be a well-documented discussion of the risks.
 Prophylactic antibiotics should be administered to all
patients being treated with leeches.
The best current evidence suggests quinolone antibi-
otic therapy, although a recent case report has reported a
MDR (multidrug resistant) aeromonas strain.103
CONCLUSION
Despite the limitations of retrieval of information
available from published series, the current paper presents
the current ‘‘best evidence’’ from a large clinical series,
and is a valuable resource which can help guide surgeons
in their use of leeches and consenting patients. Despite
the widespread use of leeches worldwide, there are insuf-
ﬁcient prospective studies with large enough numbers to
inform the microsurgical specialist on the implications of
leech speciation and Aeromonas subtypes. It is important
to note that there are proponents of alternative methods
to relieving venous congestion,105–107 and a comprehen-
sive systematic review of the chemical and mechanical
alternatives to leech therapy has been recently pub-
lished.108 Our future research efforts will aim towards an
interdisciplinary, prospective multicenter study combining
genetic clariﬁcation of leech types, hematological param-
eters, outcome analysis, and isolates from surgical
wounds.
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